LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Next Generation Sequencing Reveals Genetic Basis for Congenital Cataracts

By LabMedica International staff writers
Posted on 01 Sep 2014
Print article
Applying the latest high-throughput, next-generation DNA sequencing technology has enabled researchers in the United Kingdom to diagnose children with rare diseases that are characterized by the formation of congenital cataracts.

Diagnosing which of the more than 100 diseases that cause between 20,000 and 40,000 cases of congenital cataracts each year is often a lengthy, costly, and inconclusive process based on numerous clinical assessments and a detailed family history.

Investigators at the University of Manchester (United Kingdom) decided to modernize this process by adapting the latest high-throughput DNA sequencing technology, which is capable of simultaneously scanning for mutations in all the 115 known congenital cataracts genes.

To verify this approach, the investigators evaluated samples from 36 patients and a known positive control. They were able to determine the precise genetic cause of congenital cataracts in 75% of individuals. Among the patient group, 85% were found to have likely pathogenic mutations, all of which occurred in highly conserved domains known to be vital for normal protein function. In one case, results of DNA sequencing aided in diagnosing a patient with Warburg Micro syndrome, an extremely rare disease that is marked by an abnormally small head and the development of severe epilepsy, among other medical issues.

"There are many diseases that involve congenital cataracts but finding the exact reason was always difficult," said contributing author Dr. Graeme Black, professor of genetics and ophthalmology at the University of Manchester. "Even with a family history, diagnosing these rare diseases was always a bit of a shot in the dark."

The DNA-based test, which was described in the August 19, 2014, online edition of the journal Ophthalmology, was certified for diagnostic use by the United Kingdom's National Health Service in December 2013.

Related Links:

University of Manchester

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more